human-microbiome--grandresearchstore

Human Microbiome Market by Disease (Diabetes, Obesity,
Autoimmune, Cancer, Diarrhea, Mental Disorder),
Application (Therapeutic, Diagnostic) & by Product
(Probiotic, Prebiotic, Food, Medical Food, Supplement,
Device, Drug) – Global Forecast to 2023
Published On : September 2014
Category : Medical Devices
Pages : 146 pages
Contact : International : (+1) 646 781 7170 help@grandresearchstore.com
Report Description:
Need for early diagnosis and efficient treatment with microbiome therapy for maintaining
healthy lifestyle will boost the human microbiome market
The product segment is expected to account for the largest share of the human microbiome
market in the coming years. The high growth in this segment is attributed to the
expectations to bring promising microbiome products to the market to help individual for
the treatment of chronic diseases and various disorders at early stages and also due to
increased curiosity among people to stay fit and have healthy lifestyle . The ability of these
products to combat the fatal lifestyle diseases and maintain good health among the diseased
population with the use of effective microbiome-based drugs and diagnostics devices will
influence the market growth.
Europe currently forms the largest human microbiome market in terms of demand for
prebiotics and probiotics. The APAC region is expected to register the highest growth rate
due to its immense growth opportunities and manufacturing cost benefits, while the U.S. is

comparatively underdeveloped. Scientific evidence of health benefits of certain ingredients
such as probiotics, prebiotics, etc. and the search for new opportunities to add value to the
existing products are also expected to propel the global market growth. The demand for
prebiotics and probiotics is increasing across various regions owing to the awareness among
consumers regarding the favorable benefits of the microbiome community also referred as
“friendly” bacteria. Most of the consumers prefer these products for maintaining good
health and to use enhanced efficiency of ingredients, which offer products with
biotherapeutic properties. With the advancement in technology, the usage of probiotics is
likely to extend beyond the current arena of gut, dental, and immune health to several other
areas of human health.
Moreover, rising incidences of cardiac diseases and other diseases such as diabetes and
obesity are also expected to contribute to the growth of the human microbiome market.
Increasing side effects and diminishing of human gut flora, due to excessive use of
antibiotics, is likely to drive the growth of the human microbiome market. The application
market is also expected to be a prominent segment owing to the use of microbiome as
diagnostics and therapeutics. The evidence from intransigent research resulted the use of
microbiomes as biomarkers and diagnosis of various diseases.
The disease segment, on the other hand, will be the fastest-growing segment in the coming
years. With the growing incidences and increasing awareness of lifestyle diseases this
market is set to grow at a fast pace.
The grey area while estimating the market size was the uncertainty factor that lies with the
current regulatory scenario for various products. The insights were provided by the industry
experts who later clarified as to which disease segment will witness product approvals by
the regulatory authorities and will enter the market in the future.
From an insight perspective, this research report focuses on the qualitative data, future
market size, share, and market potential of various segments and subsegments, competitive
landscape, and company profiles. The qualitative data covers various levels of industry
analysis such as market dynamics (drivers, restraints, opportunities, and threats) and
technological trends, globally. It mainly focuses on the emerging and high-growth segments
of the human microbiome market and the initiatives of their respective governments.
The competitive landscape covers the current product pipelines of the industry players in
various stages of the clinical trial development. The company profiles comprise the basic
views on the key players in the human microbiome market and the product portfolios,
developments, and strategies adopted by market players to maintain and increase their
market shares in the near future.
The above mentioned market research data, market potential, future market size, and
forecast of future trends will help the key players and new entrants to make the necessary
decisions regarding market penetration, product development/innovation, market
development, market diversification, and competitive assessment, product offerings,

geographic focus, change in strategic approach, R&D investments for innovations in
products and technologies, and levels of output in order to remain successful in the market.
Table of contents:
TABLE OF CONTENTS
1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKETS COVERED 14
1.3 STAKEHOLDERS 15
1.4 MARKET SCOPE 15
2 RESEARCH METHODOLOGY 17
2.1 MARKET SIZE ESTIMATION 18
2.2 MARKET CRACKDOWN & DATA TRIANGULATION 21
2.3 MARKET SHARE ESTIMATION 21
2.3.1 KEY DATA FROM SECONDARY SOURCES 21
2.3.2 KEY DATA FROM PRIMARY SOURCES 22
2.3.3 KEY INDUSTRY INSIGHTS 22
2.3.4 ASSUMPTIONS 23
3 EXECUTIVE SUMMARY 24
4 PREMIUM INSIGHTS 27
4.1 ATTRACTIVE MARKET OPPORTUNITIES IN GLOBAL HUMAN MICROBIOME MARKET
27
4.2 HUMAN MICROBIOME MARKET SNAPSHOT 28
4.3 NORTH AMERIA WILL BE THE FASTEST GROWING MARKET IN THE FORECAST
PERIOD 29
4.4 HUMAN MICROBIOME MARKET: BY DISEASES 29
4.5 HUMAN MICROBIOME MARKET: BY PRODUCT 30
4.6 LIFE CYCLE ANALYSIS, BY GEOGRAPHY 30
4.7 HUMAN MICROBIOME MARKET: BY APPLICATION 31
5 MARKET OVERVIEW 32
5.1 INTRODUCTION 33
5.1.1 HUMAN MICROBIOME MARKET, BY APPLICATION 33
5.1.2 HUMAN MICROBIOME MARKET, BY DISEASE 34
5.1.3 HUMAN MICROBIOME MARKET, BY PRODUCT 34
5.2 MARKET DYNAMICS 35
5.2.1 DRIVERS 36
5.2.1.1 Human microbiome therapy, an emerging market 36
5.2.1.2 Human microbiome represents as new validated targets for drug development 37

5.2.1.3 Need for early disease detection and diagnosis driving the use of microbiomes in
molecular diagnostics 37
?
5.2.2 RESTRAINTS 38
5.2.2.1 Lack of proper detailed research 38
5.2.2.2 Barriers to prove causal link between dysbiosis and disease 38
5.2.3 OPPORTUNITIES 39
5.2.3.1 IND requirements for fecal microbiota may boost market growth 39
5.2.3.2 Joint ventures, collaborations, & partnerships between companies 39
5.2.4 THREATS 40
5.2.4.1 Government regulations 40
5.2.5 BURNING ISSUES 41
5.2.5.1 Abundant opportunities in the microbiome field and tremendous research
investments may boost the market 41
5.2.5.2 Various microbiome therapeutic products in various stages of development 42
6 INDUSTRY TRENDS 43
6.1 INTRODUCTION 43
6.2 INDUSTRY TRENDS 43
6.3 PORTER’S FIVE FORCES ANALYSIS 44
6.3.1 THREAT FROM NEW ENTRANTS 44
6.3.2 THREAT FROM SUBSTITUTES 45
6.3.3 BARGAINING POWER OF SUPPLIERS 45
6.3.4 BARGAINING POWER OF BUYERS 45
6.3.5 INTENSITY OF COMPETITIVE RIVALRY 46
6.4 PEST ANALYSIS 46
6.4.1 POLITICAL FACTORS 46
6.4.2 ECONOMIC FACTORS 46
6.4.3 SOCIAL FACTORS 47
6.4.4 TECHNOLOGICAL FACTORS 47
6.5 STRATEGIC BENCHMARKING 47
6.5.1 RESEARCH AND TECHNOLOGY INTEGRATION & PRODUCT DEVELOPMENT 47
6.5.2 ENTRY INTO THE CHRONIC LIFESTYLE DISEASES MARKET 48
7 HUMAN MICROBIOME MARKET, BY DISEASE 50
7.1 INTRODUCTION 51
7.2 DIABETES 53
7.3 OBESITY 54
7.4 AUTOIMMUNE DISORDERS 56
7.5 CANCER 57
7.6 ACUTE DIARRHEA 59
7.7 MENTAL DISORDERS 60
7.8 OTHER DISEASES 63
?
8 HUMAN MICROBIOME MARKET, BY APPLICATION 65
8.1 INTRODUCTION 66

8.2 THERAPEUTICS 68
8.3 DIAGNOSTICS 70
9 MARKET, BY PRODUCT 72
9.1 INTRODUCTION 73
9.2 PROBIOTICS 75
9.3 PREBIOTICS 77
9.4 FOODS 78
9.5 MEDICAL FOOD 80
9.6 OTHER PROBIOTIC SUPPLEMENTS 81
9.7 DEVICES 83
9.8 DRUGS 84
10 GEOGRAPHIC ANALYSIS 86
10.1 INTRODUCTION 87
10.2 NORTH AMERICA 88
10.3 EUROPE 90
10.4 ASIA-PACIFIC 92
10.5 REST OF THE WORLD (ROW) 95
11 COMPETITIVE LANDSCAPE 97
11.1 OVERVIEW 97
11.2 NEW PRODUCT LAUNCHES 99
11.3 AGREEMENTS, PARTNERSHIPS & COLLABORATIONS 99
11.4 EXPANSIONS 102
11.5 CLINICAL /RESEARCH STUDIES 102
11.6 PATENT FILLINGS AND APPROVALS 103
11.7 OTHER DEVELOPMENTS 105
12 COMPANY PROFILES 107
(Overview, Financials, Products & Services, Strategy, & Developments)*
12.1 INTRODUCTION 107
12.2 ENTEROME BIOSCIENCE 108
12.3 SECOND GENOME, INC. 111
12.4 MICROBIOME THERAPEUTICS LLC. 114
12.5 VEDANTA BIOSCIENCES, INC. 117
12.6 METABIOMICS CORPORATION 119
12.7 E.I. DU PONT DE NEMOURS AND COMPANY 122
12.8 MERCK & CO., INC. 126
12.9 YAKULT HONSHA CO., LTD. 128
12.10 OSEL, INC. 131
12.11 VITHERA PHARMACEUTICALS 133
12.12 GT BIOLOGICS LTD. 136
*Details on Financials, Product & Services, Strategy, & Developments might not be
captured in case of unlisted companies.
13 APPENDIX 139
13.1 INSIGHTS OF INDUSTRY EXPERTS 139
13.2 DISCUSSION GUIDE 140

13.3 INTRODUCING RT: REAL TIME MARKET INTELLIGENCE 143
13.4 AVAILABLE CUSTOMIZATIONS 144
1.1. RELATED REPORTS 145
Get full report details at:
http://www.grandresearchstore.com/medical-devices/human-microbiome-mark
et-by-disease-diabetes-obesity-autoimmune-cancer-diarrhea-mental-disorderapplication-therapeutic-diagnostic-26-by-product-probiotic-prebiotic-foodmedical-food-supplement-device-drug-96-global-forecast-to-2023